Treatment resistance in first-episode psychosis is characterised by altered effective connectivity between anterior cingulate and amygdala

The human brain is a vast network of regions that must constantly talk to one another to make sense of the world. Some parts of this network are like sensory stations, gathering raw information from our eyes and ears, while others act as command centers, deciding how to react to that information. In a healthy brain, these regions work in a balanced rhythm. The command centers send signals down to the sensory stations to help interpret what is being seen or heard, while the sensory stations send data up to update the command centers on what is actually happening. This two-way conversation is essential for navigating social situations, recognizing threats, and learning from rewards. When this communication breaks down, the result can be a condition known as psychosis, where a person's perception of reality becomes distorted. For decades, doctors have treated these symptoms with medications that target a specific chemical messenger in the brain called dopamine. While these drugs help many people, they fail to work for about one-third of patients. This leaves a critical question unanswered: if the standard treatment does not work for everyone, what is happening differently in the brains of those who do not respond?

A team of researchers set out to find the answer by looking at the very beginning of the illness, rather than waiting until it has been present for many years. They focused on a group of people who had just experienced their first episode of psychosis. The researchers wanted to see if the way different brain regions communicated with each other could predict whether a patient would eventually respond to medication or remain resistant to it. They used a specialized scanning technique to watch the brain in action while the participants performed a simple task. The participants were asked to look at pairs of faces on a screen—some smiling, some angry, and some with neutral expressions—and choose which one was more likely to win them a small monetary reward. As they played, the scanner recorded the flow of activity between key areas of the brain, specifically looking at how the command centers influenced the regions that process emotions and threats.

The study involved fifty-three patients and sixteen healthy volunteers. After scanning the patients during their first episode, the researchers followed them for a year to see how they fared with treatment. By the end of that year, they could clearly separate the patients into two groups: those whose symptoms improved significantly with medication, and those whose symptoms persisted despite adequate treatment. When the researchers looked back at the brain scans taken at the very start of the illness, a distinct pattern emerged. In the patients who eventually responded well to medication, the connection between the brain's emotional processing center and its command center was surprisingly weak. Specifically, the flow of signals from the command center down to the emotional center was reduced compared to the healthy volunteers. This suggests that at the earliest stage of the illness, those who would later recover were not exerting as much top-down control over their emotional reactions as healthy people do.

In contrast, the patients who did not respond to medication showed a different picture. Their brain scans revealed no such difference from the healthy volunteers; the connection between the command center and the emotional center appeared normal. This finding challenges the idea that treatment resistance is simply a more severe version of the same problem seen in everyone else. Instead, it suggests that the brains of treatment-resistant patients are fundamentally different from the start. They do not show the same early disruption in communication that characterizes those who will eventually recover. The researchers also noted that this pattern differs from what has been seen in patients with long-term, chronic schizophrenia. In those older studies, patients who responded to medication showed an increased connection between these regions, as if their brains had strengthened their control mechanisms over time to compensate for the illness. The new study suggests a different path: those who respond to treatment start with a weaker connection that may strengthen as they recover, while those who do not respond never develop this compensatory change.

The researchers were careful to note that these differences were not linked to the severity of the patients' symptoms, such as how many hallucinations or delusions they experienced. This implies that the way the brain regions talk to each other is a separate issue from the intensity of the symptoms themselves. The findings point toward a biological mechanism involving a different chemical messenger, glutamate, which is responsible for the communication between these brain regions. Since current medications target dopamine, they may not be able to fix the specific communication breakdown that occurs in treatment-resistant patients. The study does not offer a new cure, but it provides a clearer map of the problem. By identifying that the brains of treatment-resistant patients look different from the very beginning, the research suggests that future treatments might need to target the glutamate system to help restore the balance between the brain's command centers and its emotional responses. This work highlights that the journey of psychosis is not a single path for everyone, and understanding these early differences could be the key to helping those who have so far been left behind by standard care.